{"organizations": [], "uuid": "b7b3eab4bfee7a36458832527adc058837307a89", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fennec-says-phase-3-siopel-6-study/brief-fennec-says-phase-3-siopel-6-study-met-primary-endpoint-idUSASC09TK8", "country": "US", "domain_rank": 408, "title": "BRIEF-Fennec Says Phase 3 SIOPEL 6 Study Met Primary Endpoint", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.038, "site_type": "news", "published": "2018-03-26T18:37:00.000+03:00", "replies_count": 0, "uuid": "b7b3eab4bfee7a36458832527adc058837307a89"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fennec-says-phase-3-siopel-6-study/brief-fennec-says-phase-3-siopel-6-study-met-primary-endpoint-idUSASC09TK8", "ord_in_thread": 0, "title": "BRIEF-Fennec Says Phase 3 SIOPEL 6 Study Met Primary Endpoint", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "siopel", "sentiment": "negative"}, {"name": "fennec pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - Fennec Pharmaceuticals Inc:\n* FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2017 FINANCIAL RESULTS\n* PHASE 3 SIOPEL 6 STUDY MET PRIMARY ENDPOINT * FENNEC - SIOPEL 6 STUDY SHOWED ADDITION OF STS SIGNIFICANTLY REDUCES INCIDENCE OF CISPLATIN-INDUCED HEARING LOSS WITHOUT EVIDENCE OF TUMOR PROTECTION\n* QTRLY ‍LOSS PER SHARE $0.15​ * FENNEC - ‍BELIEVES CASH & CASH EQUIVALENTS ON HAND AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED COMMERCIAL LAUNCH OF PEDMARK (TM) IN H2 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T18:37:00.000+03:00", "crawled": "2018-03-27T11:37:13.020+03:00", "highlightTitle": ""}